Related Experiment Video
Updated: Aug 6, 2026
04:01
Revealing the Ferroptotic Phenotype of Medulloblastoma
Published on: March 15, 2024
Targeting m6A Modifications Regulating Ferroptosis Offers Novel Therapy in Diseases
Lida Du1, Joshua S Fleishman2, Shuang Wu3
1Division of Neurobiology, Johns Hopkins University, Baltimore, Maryland, USA.
Cell Proliferation
|July 17, 2026
Summary
Ferroptosis, a cell death process, is linked to many diseases. N6-methyladenosine (m6A) RNA modifications regulate ferroptosis, offering new therapeutic targets for various conditions.
Area of Science:
- Biochemistry
- Molecular Biology
- Pathology
Background:
- Ferroptosis is a regulated cell death pathway driven by iron-dependent lipid peroxidation.
- It is implicated in the pathogenesis of neurological, cardiovascular, hepatic, pulmonary, and renal disorders.
- N6-methyladenosine (m6A) is the most abundant reversible RNA modification, crucial for gene regulation.
Purpose of the Study:
- To explore the molecular mechanisms of m6A modifications and ferroptosis.
- To detail the interactions between m6A and ferroptosis in disease progression.
- To evaluate therapeutic strategies targeting m6A regulators for ferroptosis modulation.
Main Methods:
- Literature review of molecular mechanisms.
- Analysis of m6A regulation in ferroptosis.
- Evaluation of therapeutic potential of targeting m6A regulators.
Main Results:
- m6A modifications are increasingly linked to the regulation of ferroptosis.
- These interactions are important in various disease mechanisms.
- Targeting m6A regulators shows therapeutic promise for ferroptosis-related diseases.
Conclusions:
- m6A modifications play a significant role in regulating ferroptosis.
- Targeting m6A regulators offers novel therapeutic avenues for diseases involving ferroptosis.
- Further research into m6A- ferroptosis interplay can advance treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:16Necrosis
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become anucleated and die, but their...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become anucleated and die, but their...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...